Cargando…
Hepatic targeting of the centrally active cannabinoid 1 receptor (CB(1)R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes
Over-activation of the endocannabinoid/CB(1)R system is a hallmark feature of obesity and its related comorbidities, most notably type 2 diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD). Although the use of drugs that widely block the CB(1)R was found to be highly effective in treating...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science Publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900386/ https://www.ncbi.nlm.nih.gov/pubmed/36442615 http://dx.doi.org/10.1016/j.jconrel.2022.11.040 |